Sun Pharma plans to raise QIP worth Rs 12,000 crore

12 Sep 2014 Evaluate

Sun Pharmaceutical Industries, India’s largest drug maker by value, is planning to raise Rs 12000 crore through qualified institutional placement (QIP) route. In this regard, the company is seeking shareholders’ approval at its 27th annual general meeting to be held by the end of September.

Last year, there were reports that Sun Pharma was in talks to buy Sweden's Meda AB for a sum between $5 billion and $6 billion, to boost its generics business in developed markets.

Recently, the surprise inspection took place due to an increased number of recalls from the plant. Sun Pharma recalled 40,000 bottles of Venlafaxine Hydrochloride extended-release tablets, Gemcitabine and Metformin, manufactured at Halol from the US market in past few months.

Sun Pharma Inds. Share Price

1634.40 21.85 (1.35%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×